Quest Appoints Brian Brugman as Director of Research
Quest Partners LLC (“Quest”), a quantitative investment firm managing nearly $1.8 billion of assets on behalf of some of the world’s largest institutions, today announced that Brian Brugman joined the firm as Director of Research. In the role, Mr. Brugman will spearhead Quest’s research and investment strategy development alongside Quest’s Founder and Chief Investment Officer, Nigol Koulajian. He will also join Quest’s management committee.
“Brian’s breadth of experience in designing quantitative strategies with considerations around convexity risk bodes well with Quest’s differentiated approach to systematic macro trading,” said Mr. Koulajian. “He is joining as we are nearing the completion of a multi-year process to build out a state-of-the-art investment infrastructure to dramatically increase the efficiency and scalability of our research process. Brian will play a critical role in leveraging that technology and our research team to pursue highly valuable, negatively correlated returns with strong positive Alpha for our clients.”
Prior to joining Quest, Mr. Brugman spent fourteen years at AllianceBernstein where he was a Senior Vice President and Portfolio Manager on the Multi-Asset Solutions team. At AllianceBernstein, he managed the firm’s Systematic Macro strategies since their inception and played a leading role in the development of the team’s capabilities and processes. Mr. Brugman holds a Ph.D. in Physics from the University of California, Los Angeles and a B.S. in Physics and Applied Mathematics from the University of California, Riverside.
“Brian’s background and skillset are highly accretive to our team and will support our goal to always be at the forefront of the systematic investing community. We are thrilled to have him, and I greatly look forward to our collaboration,” said Paul Czkwianianc, a Partner of Quest and special advisor.
Quest is a quantitative investment advisor based in New York with approximately $1.8 billion in assets under management. Quest was founded by Nigol Koulajian in March 2001 to pursue the development of specialized quantitative investment strategies with a focus on the impact of convexity in markets. Quest’s strategies seek to generate large, positively skewed returns while maintaining a long-volatility profile with strong hedging characteristics, particularly during tail events that cause surprise losses in hedge fund and equity portfolios. Quest currently manages assets for some of the world’s leading pensions, family offices, ultra-high-net-worth individuals, and other institutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Quest Partners LLC
Director of Business Development and Investor Relations
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
P&G Puts Athletes Who Lead with Love Center Stage at Olympic Games Tokyo 2020, Celebrating Their Efforts and Inspiring Positive Action in Others5.8.2021 21:49:00 EEST | Press release
As an Olympic sponsor for the past 10 years, Procter & Gamble’s (NYSE: PG) focus is on celebrating and supporting the unique journeys athletes take on the road to their Olympic dreams, including the causes they champion and the work they do to drive positive change in their communities. In the lead up to the Olympic Games Tokyo 2020, P&G was inspired by the selfless actions of Olympic and Paralympic athletes around the world who stepped up and served others. This led P&G to create the Athletes for Good Fund in partnership with the International Olympic Committee (IOC) and International Paralympic Committee (IPC). Its purpose is to honor and fuel the work of Olympic and Paralympic athletes and hopefuls who lend their time, talent, and resources to charitable causes in the areas of Community Impact, Equality & Inclusion, and Environmental Sustainability. For Tokyo 2020, Athletes for Good Fund provided more than $500,000 in grants to help fuel the efforts of the recipients’ charities of c
Champion® Athleticwear Unveils Second Capsule in Muhammad Ali Collection5.8.2021 20:02:00 EEST | Press release
Champion, makers of authentic athletic apparel since 1919, and Muhammad Ali Enterprises, today dropped the second, limited-edition capsule in Champion’s Muhammad Ali Collection. The capsule’s new designs and fresh colors are fabricated to evoke the ethos of the sports legend during his inspirational gold medal win during the 1960 Games in Rome as an 18-year-old. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005624/en/ With details based on the 1960 Games historic location and team uniforms, Champion's Muhammad Ali collection features unique athletic accents, iconic silhouettes, luxe fabrics and voluminous draping. The men’s and women’s apparel includes Reverse Weave® hoodies, quarter-zip pullovers, joggers, shorts, graphic T-shirts, crop tops, bike shorts, hats and a special satin boxing robe. The collection is being distributed via Champion.com and Champion retail stores with distribution in the United States, Europe
Täydennys tarjousasiakirjaan koskien Adapteo Oyj:n hallituksen suosittelemaa julkista käteisostotarjousta Adapteo Oyj:n osakkeenomistajille on julkaistu5.8.2021 19:17:00 EEST | Tiedote
Palace Bidco Oy (”WSIP Bidco”), joka on West Street Global Infrastructure Partners IV, L.P.:n lukuun perustettu ja sen välillisesti kokonaan omistama yksityinen osakeyhtiö, julkisti 17.5.2021 Adapteo Oyj:n (”Adapteo”) hallituksen suositteleman julkisen käteisostotarjouksen Adapteon osakkeenomistajille kaikkien Adapteon osakkeiden hankkimiseksi WSIP Bidcolle (”Ostotarjous”). WSIP Bidco tarjoaa 165 Ruotsin kruunua kustakin Adapteon osakkeesta. Ostotarjousta koskeva tarjousasiakirja julkaistiin 23.6.2021 (”Tarjousasiakirja”). WSIP Bidco on laatinut Tarjousasiakirjaa koskevan täydennysasiakirjan (”Täydennysasiakirja”), joka on julkaistu tänään. Täydennysasiakirja on laadittu liittyen 3.8.2021 julkistettuun Adapteon osavuosiselvitykseen tammi-kesäkuulta 2021, täydentäviin tietoihin koskien euroissa maksettavaa selvitysmaksua niille Adapteon osakkeenomistajille, joiden osakkeet on rekisteröity suoraan Euroclear Finlandissa, sekä Ruotsin arvopaperilautakunnan lausuntoon AMN 2021:39 liittyen G
Moody’s Analytics Earns #2 Overall Ranking in Chartis Research STORM505.8.2021 17:15:00 EEST | Press release
Moody’s Analytics is #2 in the inaugural Chartis Research STORM50 (Statistical Techniques, Optimization frameworks and Risk Models) ranking of the world’s leading providers of quantitative solutions for the financial industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005744/en/ Chartis’ STORM50 ranking measures the strength of solutions in quantitative modeling and software, assessing the level of innovation and the quality of the underlying computational infrastructure. The scoring is based on five criteria: breadth and coverage, impact, computational infrastructure, innovation, and strategy. In addition to the #2 ranking overall, Moody’s Analytics placed first in 14 of 55 categories, including Breadth & Coverage, Impact, Strategy, and Innovation, evidencing the depth of the company’s modeling expertise. “The inaugural Chartis Research STORM50 ranking highlights our ability to deliver an integrated view of risk
Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine5.8.2021 16:30:00 EEST | Press release
Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples. Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneous
Andersen Global Strengthens Puerto Rican Coverage with Tax and Advisory Firm5.8.2021 16:30:00 EEST | Press release
Andersen Global adds dimension to its platform in Puerto Rico with the addition of collaborating firm AFS CPA Group LLC (AFS), solidifying its presence in the country with tax and legal coverage. AFS provides tax and advisory services to clients including individuals and small and large businesses, serving a variety of industries such as legal, medical, food and restaurants, apparel, marketing, technology, non-profit and homeowners associations. The firm, established in 2000 by Founder and Managing Partner Antonio Sécola, is based in Gurabo and offers tax, financial, investment and cash management services as well as outsourcing and payroll functions. “As an Arthur Andersen alumnus, I look forward to rejoining the culture and working with like-minded individuals who are committed to serving clients best-in-class solutions,” Antonio said. “Our firm is dedicated to providing the highest quality service, and this collaboration further supplements our ability to deliver seamless solutions
Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine5.8.2021 16:00:00 EEST | Press release
Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine. The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines. The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom